{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:36:58Z","timestamp":1785307018341,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jdin.2023.04.014","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T15:15:05Z","timestamp":1686410105000},"page":"117-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims data"],"prefix":"10.1016","volume":"13","author":[{"given":"Heide A.","family":"Stirnadel-Farrant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kwiatek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Candrilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Datto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jdin.2023.04.014_bib1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: a systematic review and meta-analysis","volume":"186","author":"Persson","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdin.2023.04.014_bib2","article-title":"A blistering new era for bullous pemphigoid: a scoping review of current therapies, ongoing clinical trials, and future directions","volume":"70","author":"Khalid","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"issue":"2","key":"10.1016\/j.jdin.2023.04.014_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2023.04.014_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","article-title":"Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009","volume":"71","author":"Brick","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jdin.2023.04.014_bib5","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1111\/jocd.14797","article-title":"Global incidence and prevalence of bullous pemphigoid: a systematic review and meta-analysis","volume":"21","author":"Lu","year":"2022","journal-title":"J Cosmet Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2023.04.014_bib6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaad.2018.08.030","article-title":"Prevalence estimates for pemphigoid in the United States: a sex-adjusted and age-adjusted population analysis","volume":"80","author":"Wertenteil","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2023.04.014_bib7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/bjd.12072","article-title":"British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012","volume":"167","author":"Venning","year":"2012","journal-title":"Br J Dermatol"},{"issue":"7662","key":"10.1016\/j.jdin.2023.04.014_bib8","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jdin.2023.04.014_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00403-020-02100-2","article-title":"Association of bullous pemphigoid and comorbid health conditions: a case-control study","volume":"313","author":"Lee","year":"2021","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"10.1016\/j.jdin.2023.04.014_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"5","key":"10.1016\/j.jdin.2023.04.014_bib11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.0022-202X.2004.22504.x","article-title":"Mortality rate of bullous pemphigoid in a US medical center","volume":"122","author":"Colbert","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2023.04.014_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archderm.134.4.465","article-title":"High risk of death in elderly patients with extensive bullous pemphigoid","volume":"134","author":"Roujeau","year":"1998","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2023.04.014_bib13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archderm.138.7.903","article-title":"Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age","volume":"138","author":"Rzany","year":"2002","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.jdin.2023.04.014_bib14","first-page":"Cr360","article-title":"Epidemiological and clinical analysis of pemphigoid patients in northeastern Poland in 2000-2005","volume":"13","author":"Serwin","year":"2007","journal-title":"Med Sci Monit"},{"issue":"4","key":"10.1016\/j.jdin.2023.04.014_bib15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2008.07.022","article-title":"Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States","volume":"59","author":"Parker","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jdin.2023.04.014_bib16","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jclinepi.2008.01.006","article-title":"The Charlson comorbidity index is adapted to predict costs of chronic disease\u00a0in\u00a0primary care patients","volume":"61","author":"Charlson","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.jdin.2023.04.014_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328723000871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328723000871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:01:33Z","timestamp":1762981293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328723000871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":17,"alternative-id":["S2666328723000871"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2023.04.014","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims data","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2023.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}